Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City

Anthropic and Accenture (ACN) announced a partnership to independently evaluate Anthropic's AI models, with each committing at least $1 billion over five years. The move comes amid rising safety concerns and regulatory pressure on AI developers. Accenture's Faculty unit will lead the evaluation, conducting assessments and testing safeguards. The partnership aims to address risks and benefits of advanced AI models, with a focus on safety and transparency.

Samsung Electronics invested $214M in Dutch AI chip startup Euclid, focusing on processor-memory co-design for AI inference. Euclid's Craftwork system aims to improve efficiency by integrating compute and memory, reducing data-transfer time and power consumption. Samsung seeks to expand beyond HBM production into AI compute and memory architectures, targeting the growing inference market.

TG Therapeutics (TGTX) shares rose 5% after Bank of America raised its price target to $20 from $17, despite an 'Underperform' rating. The company launched a mid-stage trial for Briumvi in treatment-resistant schizophrenia. Analysts focus on Q2 U.S. revenue for Briumvi, with estimates around $229M, exceeding the company's $220M guidance. TGTX has gained 95% year-to-date.

Arrowhead Pharmaceuticals (ARWR) is amending a study to add a multidose portion in mixed-hyperlipidemia patients before a Phase III study. The company reported smooth launch progress for plozasiran in familial chylomicronemia syndrome (FCS) and plans to seek approval in severe hypertriglyceridemia (SHTG). Arrowhead expects to provide further details on additional dimer candidates in 2027. The company's current net price for plozasiran is $45,000 annually. Arrowhead is also developing programs in

Melius Research analyst Ben Reitzes set a $165 price target on Intel (INTC), with a potential $200 valuation in two years, citing separate valuations of its product and foundry businesses. Intel's stock has risen 157% this year, and Reitzes' target is significantly higher than the average $117.56 target among analysts. The call is based on Intel securing major foundry clients and maintaining price increases. Intel's next earnings report is awaited to assess progress.

Anthropic partners with Accenture's Faculty to evaluate its AI models, investing at least $1 billion over five years. The collaboration aims to 'red-team' models, with funding initially from Anthropic but potentially shifting to pooled or government sources. Over 100 AI researchers, including Geoffrey Hinton, advocate for independent evaluators in a public letter, according to the company.